Welcome to our dedicated page for Burzynski Resh Inst SEC filings (Ticker: BZYR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Burzynski Resh Inst's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Burzynski Resh Inst's regulatory disclosures and financial reporting.
Burzynski Research Institute (BZYR) filed its Q2 2025 10‑Q, showing continued operating losses and heavy reliance on related‑party funding. The company reported a net loss of
Liquidity remains strained: cash was
The company’s IND 43742 is under a full clinical hold, and management discloses substantial doubt about the ability to continue as a going concern within one year. Operations and clinical activities are funded under a Research Funding Agreement with Dr. Burzynski; the 10‑Q notes the company may need additional capital even with ongoing related‑party support.
FAQ
What is the current stock price of Burzynski Resh Inst (BZYR)?
